The potential of (223)Ra and (18)F-Fluoride imaging to predict bone lesion response to treatment with (223)Ra-Dichloride in castration resistant prostate cancer

por Murray, Iain, Chittenden, Sarah J., Denis-Bacelar, Ana M., Hindorf, Cecilia, Parker, Christopher C., Chua, Sue, Flux, Glenn D.
Publicado en Eur J Nucl Med Mol Imaging (2017)

InfuShield: a shielded enclosure for administering therapeutic radioisotope treatments using standard syringe pumps

por Rushforth, Dominic P., Pratt, Brenda E., Chittenden, Sarah J., Murray, Iain S., Causer, Louise, Grey, Matthew J., Gear, Jonathan I., Du, Yong, Flux, Glenn D.
Publicado en Nucl Med Commun (2017)

Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy

por Denis-Bacelar, Ana M, Chittenden, Sarah J, McCready, V Ralph, Divoli, Antigoni, Dearnaley, David P, O’Sullivan, Joe M, Johnson, Bernadette, Flux, Glenn D
Publicado en Br J Radiol (2018)

Phase I/II trials of (186)Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival

por Denis-Bacelar, Ana M., Chittenden, Sarah J., Dearnaley, David P., Divoli, Antigoni, O’Sullivan, Joe M., McCready, V. Ralph, Johnson, Bernadette, Du, Yong, Flux, Glenn D.
Publicado en Eur J Nucl Med Mol Imaging (2016)

A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases

por Denis-Bacelar, Ana M, Chittenden, Sarah J, Murray, Iain, Divoli, Antigoni, Ralph McCready, V, Dearnaley, David P, O’Sullivan, Joe M, Johnson, Bernadette, Flux, Glenn D
Publicado en Phys Med Biol (2017)